
    
      The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI
      (irinotecan, 5-fluorouracil and folinic acid) versus Best Supportive Care in third or fourth
      line treatment of patients with metastatic colorectal cancer.
    
  